Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis

Xavier M Teitsma*, Johannes W G Jacobs, Pascal H P de Jong, Johanna M W Hazes, Angelique E A M Weel, Paco M J Welsing, Attila Pethö-Schramm, Michelle E A Borm, Jacob M van Laar, Johannes W J Bijlsma, Floris P J G Lafeber

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
Original languageEnglish
Pages (from-to)142-144
Number of pages3
JournalAnnals of the Rheumatic Diseases
Volume78
Issue number1
DOIs
Publication statusPublished - Jan 2019

Bibliographical note

Funding:
The U-Act-Early trial was funded by Roche Nederland BV and the work
within the tREACH trial was supported by an unrestricted grant from Pfizer

Research programs

  • EMC OR-01

Cite this